The NBI added 0% during 2021, compared to S&P500 27% or Dow Jones’ 19%. The market kept setting new highs despite plenty of challenges, including rising inflation, global supply chain disruptions and outbreaks of more contagious variants of the Covid-19 virus.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
The Nasdaq Biotech Index has the same value as in January 2021
Monthly market moves of selected competitors compared to NASDAQ Biotechnology Index (NBI).
ADC Therapeutics
ADC T. announced six data presentationsfrom the ongoing trials of Zynlonta and ADCT-602 at ASH. This included presentations from investigators on subset data from pivotal Phase 2 study and data on the use of Zynlonta post-CAR-T.
Immunogen
ImmunoGen announced that updated initial safety and efficacy findings from Phase 1b/2 study of IMGN632 in combination with Vidaza (azacitidine) and Venclexta (venetoclax) in patients with relapsed or refractory AML were presented in oral session at ASH.
Mersana Therapeutics
Mersana participated in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.
Seagen
Seagen and Astellas announced that the EMA’s CHMP has adopted a positive opinion, recommending approval of the ADC Padcev (enfortumabvedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and a PD-1/L1 inhibitor.
Alkermes
Alkermes participated in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference.
ImmunityBio
ImmunityBio has successfully raised an aggregate $470 million of equity and debt financing in 2021, with $300 million in new debt financing from NantCapital. With this new financing from ImmunityBio’s Patrick Soon-Shiong, the company is well positioned to pursue its late-stage clinical portfolio, expand large-scale GMP manufacturing capacity, and advance recruitment of a commercial organization in the urology market.
Nektar Therapeutics
Nektar announced two data presentations from the dose-escalation portion of its ongoing Phase 1 study of NKTR-255 in patients with relapsed or refractory hematologic malignancies at ASH. The data underscore the potential of NKTR-255 and provide clinical evidence of its unique ability to trigger the induction of natural killer and CD8+ T cells and highlight its potential role in rescuing and enhancing CAR-T cell persistence.
Xencor
Xencor presented at ASH data from Phase 1 dose-escalation study of plamotamab, a CD20 x CD3 bispecific antibody, in patients with B-cell NHL. Plamotamab is generally well tolerated and demonstrates encouraging clinical activity in heavily pretreated patients at our recommended intravenous Phase 2 dose of 50 mg flat dosing every two weeks following step-up dosing.
Allogene Therapeutics
Allogene reported updated data from two Phase 1 clinical trials (ALPHA and ALPHA2) of its lead anti-CD19 AlloCAR T therapy programs (ALLO-501 and ALLO-501A) at ASH. Data from the trials continue to validate the promise of AlloCAR T platform to be a safe and durable alternative to approved autologous CAR T therapies.
Autolus Therapeutics
Autolus presented further progress on obe-cel in an oral presentation at ASH. The company also presented an update of obe-cel in relapsed or refractory aggressive and indolent B-Cell NHL and CLL patients from the ALLCAR19 extension study, as well as preclinical and initial engraftment data with AUTO1/22 in Pediatric ALL in two poster presentations.
Bellicum Pharmaceuticals
Bellicum announced positive interim data from its ongoing Phase 1/2 GoCAR-T trials, including a confirmed partial response in the first cohort of mCRPC patients treated in the clinical trial for BPX-601. Bellicum has also entered into an agreement for a $35 million private placement of equity securities with two biotechnology specialist investment funds. Proceeds will be used to support development of BPX-601 and BPX-603.
Mustang Bio
Mustang announced updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell NHL and CLL. Investigators observed 95% ORR, 65% CRR and favorable safety profile in patients treated with modified cell manufacturing process.
Arcus Biosciences
Arcus and Gilead announced the closing of Gilead’s option exercises to three programs in Arcus’s clinical-stage portfolio and a new research collaboration between the two companies.
Immutep
Immutep announced it has signed a Manufacturing Service Agreement (MSA) with Northway Biotech, an end-to-end biopharmaceutical contract development and manufacturing organization, to manufacture IMP761 ahead of clinical testing.
Clovis Oncology
Clovis presented at the 3rd Targeted Radio-pharmaceuticals Summit, reviewing the company’s preclinical data and described Phase 1/2 study currently enrolling for its targeted radiotherapy candidate FAP-2286, the first PTRT and imaging agent targeting FAP to enter clinical development.
